Introduction The Magneto Microcatheter is a novel thrombectomy system utilizing electric forces to bind clots for facilitating removal of thromboemboli associated with acute stroke. We report herein one of the patients treated as part of a First in Human study evaluating the eTrieve technology for the treatment of stroke.

Case Description The patient was a 66-year-old male. He was admitted to our hospital on 6 Jan 2022, and was diagnosed with acute ischemic stroke (M1 occlusion, confirmed by DSA). ASPECT score was 9, NIHSS was 10, pre-Stroke mRS was 0. ECG at screening showed atrial fibrillation, known from the medical history. Chest X-Ray was abnormal, demonstrating pneumonia. Patient was treated with tPA.

Medical history included DM, Hypertension, CHF, AF, Prostate Hyperplasia, and Pneumonia.

Patient was last seen well 2 hours and 45 minutes prior to admission. All inclusion criteria were met, the patient signed ICF, and was enrolled to the Magneto Microcatheter study.

Results A Boston Guider Softip 8F guiding catheter was used. Sofia Plus 6F was placed in the terminal ICA. First and only attempt was done with the Magneto Microcatheter. TICI prior to treatment was 1, after the first attempt with the Magneto Microcatheter TICI was 2C. No change in vital signs or any AE were reported during the use of Magneto Microcatheter.

• Download figure
• Open in new tab
• Download powerpoint

Abstract O28 Figure 1

On POD 2 the patient experienced a non-ST-elevation Myocardial Infarction. PCI was performed and a DES was implanted. The patient completed his 90 days follow-up visit demonstrating mRS 0 with no reported adverse events.

Disclosure of Interest no.